Effect of omega-3 fatty acid supplementation on cancer incidence, non-vascular death, and total mortality: a meta-analysis of randomized controlled trials

BMC Public Health

Yu-Hao Zhou¹  An-Ji Hou²  Hong-Fang Gao²  Yu-Fei Zhang² 

[1] Department of Rehabilitation Institute, Shanghai Seventh People’s Hospital, Shanghai 200137, China;Department of Oncology, Shanghai Seventh People’s Hospital, Shanghai, China

关键词: Meta-analysis;    Mortality;    Cancer;    Omega-3 fatty acid;   

Others  :  1132443
DOI  :  10.1186/1471-2458-14-204

 received in 2013-10-16, accepted in 2014-01-25,  发布年份 2014

【 摘 要 】

Background

Omega-3 fatty acids are known to prevent cardiac death. However, previous observational studies have suggested that omega-3 fatty acids are associated with cancer risk in adults. We conducted a meta-analysis based on randomized controlled trials to evaluate the effect of omega-3 fatty acids on the risk of cancer incidence, nonvascular death, and total mortality.

Methods

In February 2013, we performed electronic searches in PubMed, EmBase, and the Cochrane Library to identify randomized controlled trials on cancer incidence, nonvascular death, and total mortality. Relative risk (RR) was used to measure the effect of omega-3 fatty acid supplementation on the risk of cancer incidence, nonvascular death, and total mortality using a random-effect model. The analysis was further stratified by factors that could affect the treatment effects.

Results

Of the 8,746 identified articles, we included 19 trials reporting data on 68,954 individuals. These studies reported 1,039 events of cancer, 2,439 events of nonvascular death, and 7,025 events of total mortality. Omega-3 fatty acid supplementation had no effect on cancer incidence (RR, 1.10; 95% CI: 0.97–1.24; P = 0.12), nonvascular death (RR, 1.00; 95% CI: 0.93–1.08; P = 1.00), or total mortality (RR, 0.95; 95% CI: 0.88–1.03; P = 0.24) when compared to a placebo. Subgroup analysis indicated that omega-3 fatty acid supplementation was associated with a reduction in total mortality risk if the proportion of men in the study population was more than 80%, or participants received alpha-linolenic acid.

Conclusions

Omega-3 fatty acid supplementation does not have an effect on cancer incidence, nonvascular death, or total mortality.

【 授权许可】

   
2014 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Kato I, Akhmedkhanov A, Koenig K, Toniolo PG, Shore RE: Prospective study of diet and female colorectal cancer: the New York University Women’s Health Study. Nutr Cancer 1997, 28:276-281.
• [2]Takezaki T, Inoue M, Kataoka H, Ikeda S, Yoshida M: Diet and lung cancer risk from a 14-year population-based prospective study in Japan: with special reference to fish consumption. Nutr Cancer 2003, 45:160-167.
• [3]Terry P, Bergkvist L, Holmberg L, Wolk A: No association between fat and fatty acids intake and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001, 10:913-914.
• [4]Baronzio G, Freitas I, Griffini P, Bertone V, Pacini F: Omega-3 fatty acids can improve radioresponse modifying tumor interstitial pressure, blood rheology and membrane peroxidability. Anticancer Res 1994, 14:1145-1154.
• [5]Avula CPR, Lawrence RA, Jolly CA, Fernandes G: Role of n-3 polyunsaturated fatty acids (PUFA) in autoimmunity, inflammation, carcinogenesis, and apoptosis. Recent Res Develop Lipids 2000, 4:303-319.
• [6]Johnson IT: Anticarcinogenic effects of diet related apoptosis in the colorectal mucosa. Food Chem Toxicol 2002, 40:1171-1178.
• [7]Borchgrevink CF, Skaga E, Berg KJ, Skjaeggestad O: Absence of prophylactic effect of linolenic acid in patients with coronary heart-disease. Lancet 1966, 2:187-189.
• [8]Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989, 2:757-761.
• [9]Rossing P, Hansen BV, Nielsen FS, Myrup B, Holmer G: Fish oil in diabetic nephropathy. Diabetes Care 1996, 19:1214-1219.
• [10]von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H: The effect of dietary omega-3 fatty acids on coronary atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 130:554-562.
• [11]GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455.
• [12]Nilsen DW, Albrektsen G, Landmark K, Moen S, Aarsland T: Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 2001, 74:50-56.
• [13]Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P: Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003, 57:193-200.
• [14]Raitt MH, Connor WE, Morris C, Kron J, Halperin B: Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators. A randomized controlled trial. JAMA 2005, 293:2884-2891.
• [15]Brouwer IA, Zock PL, Camm AJ, Bocker D, Hauer RN: Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the study on omega-3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. JAMA 2006, 295:2613-2619.
• [16]Japan EPA lipid intervention study (JELIS) Investigators: Eff ects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
• [17]SU.FOL.OM3 Collaborative Group: Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010, 341:c6273.
• [18]Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Medicine 2009, 6:e1000097.
• [19]Jadad AR, Moore RA, Carroll D: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17:1-12.
• [20]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
• [21]Ades AE, Lu G, Higgins JP: The interpretation of random-effects metaanalysis in decision models. Med Decis Making 2005, 25:646-654.
• [22]Deeks JJ, Higgins JPT, Altman DG: Analyzing data and undertaking meta-analyses. In Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Edited by Higgins J, Green S. Oxford, UK: The Cochrane Collaboration: chap 9; 2008.
• [23]Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
• [24]Thompson SG, Higgins JP: How should meta-regression analyses be undertaken and interpreted? Stat Med 2002, 21:1559-1573.
• [25]Altman DG, Bland JM: Interaction revisited: the difference between two estimates. BMJ 2003, 326:219.
• [26]Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
• [27]Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
• [28]de Lorgeril M, Renaud S, Mamelle N, Sslen P, Martin JL: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994, 343:1454-1459.
• [29]Leng GC, Lee AJ, Fowkes FG, Jepson RG, Lowe GD: Randomized controlled trial of gamma-linolenic acid eicosapentaenoic acid in peripheral arterial disease. Clin Nutr 1998, 17:265-271.
• [30]Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J: Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005, 112:2762-2768.
• [31]GISSI-HF investigators: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
• [32]OMEGA Study Group: OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122:2152-2159.
• [33]Einvik G, Klemsdal TO, Sandvik L, Hjerkinn EM: A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Prev Rehabil 2010, 17:588-592.
• [34]Alpha Omega Trial Group: n–3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010, 363:2015-26.
• [35]The ORIGIN: Trial investigators: n–3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012, 367:309-318.
• [36]MacLean CH, Newberry SJ, Mojica WA, Khanna P, Issa AM: Effects of omega-3 fatty acids on cancer risk a systematic review. JAMA 2006, 295:403-415.
• [37]Bartsch H, Nair J, Owen RW: Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. Carcinogenesis 1999, 20:2209-2218.
• [38]Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T: Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 2009, 338:a2931.